Science

Crossing the borders of innovation

Basing clinical trials on sound mechanistic and scientific rationale.

Combating Pan-Cancer with Precision

Combating Pan-Cancer with Precision

Saving Lives of Patients Who Exhausted Treatment Options and Improving Clinical Benefits

Patient no box

Cancer Patients are fighting for their lives...
we will fight with them

Imagining a world without cancer.

Apollomics is an innovative biotechnology company focusing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer.

Our Vision

To become a global leader in the development of novel medicines for cancer patients.

Recent News

November 15, 2022

Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations

September 14, 2022

Apollomics Inc., a Late-Stage Clinical Biopharmaceutical Company to be Listed on Nasdaq Through Business Combination with Maxpro Capital Acquisition Corp.